--- title: "Is Ardelyx (ARDX) Pricing Reflect Its DCF Upside After Recent Share Price Volatility" type: "News" locale: "en" url: "https://longbridge.com/en/news/278239669.md" description: "Ardelyx (ARDX) is currently priced at approximately $6.19, reflecting a 5.5% decline over the past week and a 16.1% decline over the last month. Despite a 16.8% return over the past year, the stock is considered undervalued by 89.5% based on a Discounted Cash Flow (DCF) analysis, which estimates an intrinsic value of $58.79 per share. Additionally, Ardelyx's Price-to-Sales (P/S) ratio of 3.73x is below industry averages, indicating further undervaluation. Investors are encouraged to consider their own narratives regarding the company's future performance." datetime: "2026-03-08T01:38:37.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/278239669.md) - [en](https://longbridge.com/en/news/278239669.md) - [zh-HK](https://longbridge.com/zh-HK/news/278239669.md) --- # Is Ardelyx (ARDX) Pricing Reflect Its DCF Upside After Recent Share Price Volatility - If you are asking yourself whether Ardelyx at around US$6.19 is attractively priced or not, this article is going to walk through what the current market price might be implying about its value. - The share price has seen mixed returns, including a 5.5% decline over the last week and a 16.1% decline over the last month, alongside a 16.8% return over the past year and 73.9% over three years. Year to date performance is around 0.7%, and the 5 year return reflects an 11.2% decline. - Recent trading likely reflects how investors are reacting to ongoing developments around Ardelyx's pipeline, regulatory milestones, and broader sentiment toward smaller biotech names that can be sensitive to clinical and approval news. While this article does not focus on specific events, these types of headlines often frame how the market is thinking about risk and opportunity around the stock. - On our checks, Ardelyx currently holds a valuation score of 6 out of 6, which means it screens as undervalued on all six measures we apply. Next we will look at how different valuation approaches arrive at that view and why there may be an even richer way to think about value by the end of this article. Find out why Ardelyx's 16.8% return over the last year is lagging behind its peers. ### Approach 1: Ardelyx Discounted Cash Flow (DCF) Analysis A Discounted Cash Flow model takes estimates of a company’s future cash flows and then discounts them back to today’s value to see what the whole business might be worth on a per share basis. For Ardelyx, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is a loss of about $43.8 million. Analysts provide cash flow estimates out to 2029, and Simply Wall St then extrapolates further to 2035. Within that path, projected free cash flow reaches about $592.6 million in 2030, with intermediate years such as 2026 and 2027 projected at $58.4 million and $188.1 million respectively, all in dollar terms. After discounting these projected cash flows back to today, the model arrives at an estimated intrinsic value of about $58.79 per share. Compared with the current share price of around $6.19, this implies the stock is about 89.5% undervalued based on this DCF view alone. **Result: UNDERVALUED** Our Discounted Cash Flow (DCF) analysis suggests Ardelyx is undervalued by 89.5%. Track this in your watchlist or portfolio, or discover 50 more high quality undervalued stocks. ARDX Discounted Cash Flow as at Mar 2026 Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Ardelyx. ### Approach 2: Ardelyx Price vs Sales For a company like Ardelyx, where earnings are not the main anchor yet, the P/S ratio is often a more practical yardstick than P/E. It focuses on revenue rather than profit, which can still be volatile. Investors usually accept a higher or lower P/S depending on how they see growth potential and risk, so what counts as a “normal” multiple can vary a lot from one business to another. Ardelyx currently trades on a P/S of 3.73x. That sits below the Biotechs industry average P/S of 12.02x and also below the peer group average of 9.91x. Simply Wall St’s Fair Ratio for Ardelyx is 7.10x. This is a proprietary estimate of what the P/S might be, given factors such as earnings growth, industry context, profit margins, market cap and key risks. This Fair Ratio can be more tailored than a simple check against peers or the broad industry because it adjusts for company specific traits rather than treating every biotech the same. Comparing the Fair Ratio of 7.10x with the current P/S of 3.73x suggests the shares trade at a discount on this measure. **Result: UNDERVALUED** NasdaqGM:ARDX P/S Ratio as at Mar 2026 P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies. ### Upgrade Your Decision Making: Choose your Ardelyx Narrative Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives, which are simply your own story about Ardelyx that connects what you think will happen to its revenue, earnings and margins with a clear forecast and a fair value that you can compare with the current share price. On Simply Wall St's Community page, used by millions of investors, Narratives let you plug in your assumptions, see a fair value estimate, and then quickly check whether that fair value sits above or below Ardelyx's current price. This can help you decide whether it might be closer to a buy, hold or sell for your personal view. These Narratives update automatically when new information comes in, such as earnings results or news about Ardelyx. Your fair value view therefore moves with the story rather than sitting as a static spreadsheet you have to constantly maintain. For Ardelyx, one investor might build a bullish Narrative around a fair value of US$19.00 with faster revenue growth and higher margins. Another might anchor a more cautious Narrative around a fair value of US$10.00. By seeing both side by side you can decide which story, and which set of numbers, feels more realistic for you. Do you think there's more to the story for Ardelyx? Head over to our Community to see what others are saying! NasdaqGM:ARDX 1-Year Stock Price Chart _This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._ ### **New:** Manage All Your Stock Portfolios in One Place We've created the **ultimate portfolio companion** for stock investors, **and it's free.** • Connect an unlimited number of Portfolios and see your total in one currency • Be alerted to new Warning Signs or Risks via email or mobile • Track the Fair Value of your stocks Try a Demo Portfolio for Free ### Related Stocks - [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md) - [ARDX.US](https://longbridge.com/en/quote/ARDX.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [VHT.US](https://longbridge.com/en/quote/VHT.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [IHE.US](https://longbridge.com/en/quote/IHE.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [LABD.US](https://longbridge.com/en/quote/LABD.US.md) - [XLV.US](https://longbridge.com/en/quote/XLV.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) ## Related News & Research - [Phocas Financial Corp. Takes Position in BioCryst Pharmaceuticals, Inc. $BCRX](https://longbridge.com/en/news/282977301.md) - [Goldman Sachs Sticks to Their Buy Rating for Aclaris Therapeutics (ACRS)](https://longbridge.com/en/news/283014601.md) - [Aspire Biopharma Completes $21 Million Private Placement Financing](https://longbridge.com/en/news/283061868.md) - [BUZZ-Precision BioSciences up as hepatitis B gene‑editing trial expands in Europe](https://longbridge.com/en/news/282832865.md) - [Should Positive Elsunersen Data And Relutrigine Priority Review Shift the Narrative for Praxis (PRAX) Investors?](https://longbridge.com/en/news/282419526.md)